USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

Mark G. Lebwohl, MD, gives an overview of generalized pustular psoriasis (GPP) and explains how it differs from the more common plaque psoriasis.

But we know with generalized pustular psoriasis [GPP], IL-36 plays a unique role. Talk to us a little bit about what’s different in IL-36 and why is it uniquely positioned for GPP patients.

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

AAD > Psoriasis. IL-36 And Generalized Pustular Psoriasis: L'chaim! – An American Academy of Dermatology Reading Room selection March 25, 2022 Warren R. Heymann, MD, FAAD ...

Three-quarters of patients with generalized pustular psoriasis demonstrated response to treatment with an interleukin-36-targeted therapy as early as 4 weeks, according to a study.“Generalized ...

Of the 53 patients in the initial treatment group, 61.8% achieved a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 at week 1, while 84.4% did so at ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment of generalized pustular psoriasis flares in adults.. Spevigo is a humanized monoclonal ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Anaptys announces positive top-line GEMINI-2 phase 3 clinical trial results of imsidolimab (IL-36R) in generalized pustular psoriasis (GPP). News release. AnaptysBio, Inc. May 9, 2024.